Warning: The NCBI web site requires JavaScript to function. more...
Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis.
Leandro MJ.
Arthritis Res Ther. 2009;11(5):128. Epub 2009 Oct 6. Review.
Related citations
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
Arthritis Rheum. 2007 May;56(5):1417-23.
Immunological therapies for rheumatoid arthritis.
Edwards CJ.
Br Med Bull. 2005 Sep 20;73-74:71-82. Print 2005. Review.
B cell therapies for rheumatoid arthritis: beyond B cell depletion.
Calero I, Nieto JA, Sanz I.
Rheum Dis Clin North Am. 2010 May;36(2):325-43. Review.
[Anti-TNF-alpha monoclonal antibodies in the treatment of rheumatoid arthritis].
Mugnier B, Bouvenot G.
Rev Med Interne. 2000 Oct;21(10):854-62. Review. French.
No B cells--no active RA? Advances in B cell depletion in RA--repeated therapy under conditions of clinical practice.
Dörner T, Burmester GR.
Rheumatology (Oxford). 2007 Apr;46(4):563-4. Epub 2007 Mar 3. No abstract available.
Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
Bokarewa M, Lindholm C, Zendjanchi K, Nadali M, Tarkowski A.
Scand J Immunol. 2007 Oct;66(4):476-83.
Peripheral blood lymphocytes from patients with rheumatoid arthritis are differentially sensitive to apoptosis induced by anti-tumour necrosis factor-alpha therapy.
Coury F, Ferraro-Peyret C, Le Cam S, Guerin S, Tebib J, Sibilia J, Bienvenu J, Fabien N.
Clin Exp Rheumatol. 2008 Mar-Apr;26(2):234-9.
Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.
Rheumatology (Oxford). 2002 Apr;41(4):430-9.
B lymphocyte depletion therapy with rituximab in rheumatoid arthritis.
Edwards JC, Leandro MJ, Cambridge G.
Rheum Dis Clin North Am. 2004 May;30(2):393-403, viii. Review.
[Double-blind trial of the effectiveness of antibodies to interferon-gamma and tumor necrosis factor-alpha in rheumatoid arthritis (preliminary results)].
Lukina GV, Sigidin IaA, Skurkovich SV, Skurkovich BS.
Ter Arkh. 2001;73(5):12-5. Russian.
Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
Manadan AM, Block JA.
Am J Ther. 2008 Jan-Feb;15(1):53-8. Review.
Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis.
Keystone EC.
Rheum Dis Clin North Am. 2001 May;27(2):427-43. Review.
Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, Molberg Ø.
Ann Rheum Dis. 2009 Feb;68(2):249-52. Epub 2008 Aug 22.
[B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
Yukawa N, Mimori T.
Clin Calcium. 2007 Apr;17(4):569-76. Review. Japanese.
Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.
Dass S, Vital EM, Emery P.
Expert Opin Pharmacother. 2006 Dec;7(18):2559-70. Review.
Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety.
Radovits BJ, Kievit W, Laan RF.
Drugs Aging. 2009;26(8):647-64. doi: 10.2165/11316460-000000000-00000. Review.
[Value of anti-TNF-alpha molecules in inflammatory and infectious diseases].
Fautrel B, Cherin P.
Rev Med Interne. 2000 Oct;21(10):872-88. Review. French.
[Biopharmaceuticals in the treatment of rheumatoid arthritis].
Baslund B, Bendtzen K.
Ugeskr Laeger. 2008 Jun 9;170(24):2108-10. Review. Danish.
Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks.
Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, Miller CH, Dutcher PO, Hadley JA, Sanz I.
J Immunol. 2008 Jan 15;180(2):688-92.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on